Canverixin clinical trials
Also written ACT-1004-1239.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses canverixin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ACT-1004-1239
- 2
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses canverixin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT05549531Written as ACT-1004-1239 (10 mg)How we know
- Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239CompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT04286750Written as ACT-1004-1239How we know
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03869320Written as ACT-1004-1239How we know
Codes
What other systems call canverixin · ClinicalTrials.gg INT001768
- UNII (FDA) 122Q610M3RCANVERIXINOne source FDA
- NCI Thesaurus C220983CanverixinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 122Q610M3R | CANVERIXIN | One source FDA |
| NCI Thesaurus | C220983 | Canverixin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.